Core Insights - Neurocrine Biosciences, Inc. has scheduled its fourth quarter and year-end 2025 financial results conference call and webcast for February 11, 2026, at 1:30 p.m. Pacific Time [1][4] - The company is focused on developing treatments for neurological, psychiatric, endocrine, and immunological disorders, with a diverse portfolio that includes FDA-approved treatments and a robust pipeline [2] Company Overview - Neurocrine Biosciences is a leading biopharmaceutical company dedicated to discovering and developing life-changing treatments for patients with under-addressed conditions [2] - The company's portfolio includes treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, endometriosis, and uterine fibroids, with some products developed in collaboration with AbbVie [2] - The company has been applying its insights into neuroscience for three decades to address complex conditions and aims to ease the burden of debilitating diseases [2]

thSAN DIEGO, Jan. 5, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the 44 Annual J.P. Morgan Healthcare Conference at 9:45 a.m. Pacific Time on Monday, January 12, 2026, in San Francisco. Kyle Gano, Chief Executive Officer, will present at the conference. The live presentation will be webcast and can be accessed on Neurocrine Biosciences' website under Investors at www.neurocrine.com. A replay of the presentation will be available on the website approximately one hour aft ...

Conference Call and Webcast Scheduled for Tuesday, October 28 , /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its third quarter 2025 financial results conference call and webcast for 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) on October 28, 2025. The schedule for the press release and conference call / webcast is as follows: The webcast can also be accessed on Neurocrine Biosciences' website under Investors at www.neurocrine.com. A replay of the webca ...